Clinical Research Group Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The Warsaw site concentrates on immune‑mediated skin disorders such as Atopic Dermatitis. Research also covers Prurigo Nodularis. Studies address Hidradenitis Suppurativa.
- Upadacitinib versus Dupilumab
- Long‑term safety of Amlitelimab
- Eblasakimab after Dupilumab failure
- Povorcitinib for Prurigo Nodularis
- Nemolizumab safety assessment
The Clinical Research Group Sp. z o.o. in Warsaw is conducting 19 studies with five investigators, all aimed at improving treatment options for immune‑related skin conditions.
Skin and Connective Tissue Diseases
Investigations target connective‑tissue diseases like Cutaneous Lupus Erythematosus. The program also includes Discoid Lupus. Another focus is Psoriasis. Additional work explores Platysma Prominence.
- Rezpegaldesleukin in moderate‑to‑severe AD
- BMS‑986165 for plaque psoriasis
- TAK‑279 oral therapy evaluation
- NT 201 for platysma prominence
- VENT‑03 in active cutaneous lupus
The Clinical Research Group Sp. z o.o. emphasizes innovative therapies to reduce skin lesions and improve quality of life for patients with lupus, psoriasis and related disorders.
General Dermatology Research
Broader dermatology studies examine chronic itch conditions such as Pruritus. The research evaluates long‑term outcomes for Moderate to Severe Plaque Psoriasis.
- Dupilumab for chronic pruritus of unknown origin
- Long‑term safety of Dupilumab in children
- Povorcitinib rollover (STOP‑LTR) study
- Deucravacitinib versus Ustekinumab cardiovascular safety
- Extended safety of Amlitelimab
At Clinical Research Group Sp. z o.o., a patient‑centered approach drives efforts to refine diagnostics and expand therapeutic choices across diverse dermatologic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinical Research Group Sp. z o.o.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 3 | Unknown | 2022-11-10 | 2024-06-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.